Neural Omega
HealthOverviewOur approach to healthMaia CorpusFor patientsMaia ClinicalFor specialists
ResearchOverviewOur approach to researchMAR PlatformFor researchersMassa SuiteFor pharma
CompanyAboutTeam and missionMimicryThe scienceEthicsHow we workObservatoryResearch and updates
Language
Contact

Decoding autoimmunity.

Research and clinical software for autoimmune disease. Built in Madrid.

Explore our work ↓Talk to us
Verticals
Health · Research
Science
Molecular mimicry
Data
Processed in the EU1

Autoimmune disease, in figures.

Autoimmune diseases are common, chronic and costly to treat. Spending on immunology medicines keeps growing, and from 2029 the European Union will have a common legal framework for using health data in research.

1 in 10

people in a UK cohort of 22 million had at least one of 19 autoimmune diseases.2

The Lancet, 2023

+$49 bn

forecast growth in global spending on immunology medicines between 2024 and 2029, an increase of 27 %.3

IQVIA Institute, 2025

2029

the year the European Health Data Space opens the secondary use of health data for research across the EU.4

Regulation (EU) 2025/327

Care and research, on the same science.

Neural Omega Health serves the people who live with autoimmune disease and the clinicians who treat them. Neural Omega Research serves the groups and companies that study it. Each vertical has its own apps, its own audience and its own data model.

One mechanism, four points of view.

Molecular mimicry links what a patient lives, what a clinician reads, what a researcher models and what a therapy may one day target.

  1. PatientLives it.Every day recorded, with consent, can contribute evidence.
  2. ClinicianReads it.Clinical references, at the point of care.
  3. ResearcherModels it.Resemblance between proteins, at proteome scale.
  4. IndustryTargets it.Hypotheses for the earliest stage of discovery.
Read the science

Whether it can be done, and whether it should.

Ethics has its own office at Neural Omega, led by our Chief Purpose Officer, and guides every decision the company makes. Where health data, artificial intelligence or research are at stake, it rests on the four principles of bioethics.

Read our ethics
Autonomy
Data is held in trustPersonal data serves only the purpose it was given for, and the person can see it, take it and withdraw it.
Beneficence
Judgement stays with peopleOur models propose; experimental evidence and professional judgement decide.
Non‑maleficence
We say what we can defendEvery public claim matches its real level of validation.
Justice
We design for everyone affectedRepresentativeness and access count from the first decision.

A Madrid company, European in scope.

Founded
Madrid, 2025
Public funding
ENISA · NextGenerationEU
Member of
AseBio

Decode itwith us.

Clinicians, researchers, patient organisations, industry and investors: tell us who you are and your message reaches the right person.

Talk to Neural Omega →For investors
  1. Neural Omega processes personal health data in accordance with Regulation (EU) 2016/679 (General Data Protection Regulation), within the European Union.
  2. Conrad N, Misra S, Verbakel JY, et al. Incidence, prevalence, and co-occurrence of autoimmune disorders over time and by age, sex, and socioeconomic status: a population-based cohort study of 22 million individuals in the UK. Lancet. 2023;401(10391):1878–1890. doi:10.1016/S0140-6736(23)00457-9
  3. IQVIA Institute for Human Data Science. The Global Use of Medicines 2025: Outlook to 2029 (webinar presentation). June 2025. Global immunology spending in constant US dollars. iqvia.com
  4. Regulation (EU) 2025/327 of the European Parliament and of the Council on the European Health Data Space. Provisions on the secondary use of health data apply from March 2029. eur-lex.europa.eu